LONDON – Vasopharm GmbH announced that the Phase IIa trial of its nitric oxide inhibitor VAS203 not only cleared all the safety, tolerability and pharmacokinetic hurdles, but also led to "substantially improved" neurological recovery at six months in traumatic brain injury (TBI) patients.